{"id":48874,"date":"2025-11-24T21:40:48","date_gmt":"2025-11-24T13:40:48","guid":{"rendered":"https:\/\/flcube.com\/?p=48874"},"modified":"2025-11-24T21:40:50","modified_gmt":"2025-11-24T13:40:50","slug":"kelun-biotechs-sac-tmt-achieves-first-adc-io-nsclc-success","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48874","title":{"rendered":"Kelun-Biotech&#8217;s Sac-TMT Achieves First ADC-IO NSCLC Success"},"content":{"rendered":"\n<p><strong>Kelun-Biotech Biopharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6990:HKG\">HKG: 6990<\/a>) announced that <strong>sacituzumab tirumotecan (sac-TMT)<\/strong>, its proprietary <strong>TROP2 ADC<\/strong>, in combination with <strong>pembrolizumab (Keytruda)<\/strong>, achieved positive results in the <strong>Phase\u202f3 OptiTROP\u2011Lung05<\/strong> study for <strong>first\u2011line PD\u2011L1\u2011positive NSCLC<\/strong>, marking the <strong>first ADC\u2011plus\u2011immune checkpoint inhibitor regimen<\/strong> to reach a primary endpoint in front\u2011line NSCLC.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-trial-milestone\">Trial Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>sac\u2011TMT (SKB264\/MK\u20112870, Jiatailai)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Kelun\u2011Biotech (6990.HK)<\/td><\/tr><tr><td><strong>Trial<\/strong><\/td><td>OptiTROP\u2011Lung05 (Phase\u202f3)<\/td><\/tr><tr><td><strong>Regimen<\/strong><\/td><td>sac\u2011TMT + pembrolizumab vs. pembrolizumab alone<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>PD\u2011L1\u2011positive locally advanced\/metastatic NSCLC (first\u2011line)<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Progression\u2011free survival (PFS)<\/td><\/tr><tr><td><strong>Result<\/strong><\/td><td>Statistically and clinically significant PFS improvement; favorable OS trend<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>First ADC\u2011IO combo<\/strong> to hit primary endpoint in first\u2011line NSCLC<\/td><\/tr><tr><td><strong>Next Step<\/strong><\/td><td>Submit supplemental NDA to CDE\/NMPA<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Novel <strong>TROP2 ADC<\/strong> with proprietary linker\u2011payload technology<\/li>\n\n\n\n<li><strong>Current China Approvals:<\/strong> 3 indications (TNBC, EGFR+ NSCLC post\u2011TKI)<\/li>\n\n\n\n<li><strong>Global Rights:<\/strong> Partnered with <strong>MSD<\/strong> (Merck) since May\u202f2022 for development and commercialization outside Greater China<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Synergistic ADC\u2011IO activity demonstrates potential to reshape first\u2011line NSCLC treatment paradigm<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-optitrop-lung05\">Clinical Evidence \u2013 OptiTROP-Lung05<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result (sac-TMT + Keytruda)<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary (PFS)<\/strong><\/td><td>Statistically significant improvement vs. Keytruda alone<\/td><\/tr><tr><td><strong>Overall Survival<\/strong><\/td><td>Trend toward benefit (interim analysis)<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Manageable safety profile; no new signals<\/td><\/tr><tr><td><strong>IDMC Recommendation<\/strong><\/td><td>Continue study; file supplemental application<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China NSCLC Patients<\/strong><\/td><td>~780,000 new cases annually<\/td><\/tr><tr><td><strong>PD\u2011L1\u2011Positive Share<\/strong><\/td><td>~60% (468,000 patients)<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Pembrolizumab monotherapy or chemo\u2011IO combos<\/td><\/tr><tr><td><strong>Peak Sales Forecast (China)<\/strong><\/td><td><strong>\u00a54.5\u20116.0\u202fbillion<\/strong> (~US$610\u2011810\u202fmillion) by 2033<\/td><\/tr><tr><td><strong>Global Market<\/strong><\/td><td>MSD to drive ex\u2011China development; potential $2\u202fbillion+ peak<\/td><\/tr><tr><td><strong>Competitive Edge:<\/strong><\/td><td>First\u2011mover ADC\u2011IO data creates differentiation vs. standard IO monotherapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reimbursement Path:<\/strong> Supplemental NDA likely qualifies for <strong>Priority Review<\/strong>; potential NRDL inclusion <strong>2027<\/strong><\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Kelun\u2011Biotech is evaluating sac\u2011TMT in <strong>first\u2011line TNBC<\/strong> and <strong>other solid tumors<\/strong>; MSD advancing global Phase\u202fIII program<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding sac\u2011TMT\u2019s regulatory review, commercial potential, and partnership outcomes. Actual results may differ materially due to risks including NMPA approval timelines, competitive responses, and MSD collaboration execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac-TMT), its proprietary TROP2 ADC,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48876,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,17,971,1832,176],"class_list":["post-48874","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-clinical-trial-results","tag-hkg-6990","tag-kelun-biotech-biopharmaceutical","tag-msd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kelun-Biotech&#039;s Sac-TMT Achieves First ADC-IO NSCLC Success - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac-TMT), its proprietary TROP2 ADC, in combination with pembrolizumab (Keytruda), achieved positive results in the Phase\u202f3 OptiTROP\u2011Lung05 study for first\u2011line PD\u2011L1\u2011positive NSCLC, marking the first ADC\u2011plus\u2011immune checkpoint inhibitor regimen to reach a primary endpoint in front\u2011line NSCLC.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48874\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kelun-Biotech&#039;s Sac-TMT Achieves First ADC-IO NSCLC Success\" \/>\n<meta property=\"og:description\" content=\"Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac-TMT), its proprietary TROP2 ADC, in combination with pembrolizumab (Keytruda), achieved positive results in the Phase\u202f3 OptiTROP\u2011Lung05 study for first\u2011line PD\u2011L1\u2011positive NSCLC, marking the first ADC\u2011plus\u2011immune checkpoint inhibitor regimen to reach a primary endpoint in front\u2011line NSCLC.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48874\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-24T13:40:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-24T13:40:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2405.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48874#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48874\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kelun-Biotech&#8217;s Sac-TMT Achieves First ADC-IO NSCLC Success\",\"datePublished\":\"2025-11-24T13:40:48+00:00\",\"dateModified\":\"2025-11-24T13:40:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48874\"},\"wordCount\":351,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48874#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2405.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Clinical trial results\",\"HKG: 6990\",\"Kelun-Biotech Biopharmaceutical\",\"MSD\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48874#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48874\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48874\",\"name\":\"Kelun-Biotech's Sac-TMT Achieves First ADC-IO NSCLC Success - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48874#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48874#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2405.webp\",\"datePublished\":\"2025-11-24T13:40:48+00:00\",\"dateModified\":\"2025-11-24T13:40:50+00:00\",\"description\":\"Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac-TMT), its proprietary TROP2 ADC, in combination with pembrolizumab (Keytruda), achieved positive results in the Phase\u202f3 OptiTROP\u2011Lung05 study for first\u2011line PD\u2011L1\u2011positive NSCLC, marking the first ADC\u2011plus\u2011immune checkpoint inhibitor regimen to reach a primary endpoint in front\u2011line NSCLC.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48874#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48874\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48874#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2405.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2405.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kelun-Biotech's Sac-TMT Achieves First ADC-IO NSCLC Success\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48874#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kelun-Biotech&#8217;s Sac-TMT Achieves First ADC-IO NSCLC Success\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kelun-Biotech's Sac-TMT Achieves First ADC-IO NSCLC Success - Insight, China&#039;s Pharmaceutical Industry","description":"Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac-TMT), its proprietary TROP2 ADC, in combination with pembrolizumab (Keytruda), achieved positive results in the Phase\u202f3 OptiTROP\u2011Lung05 study for first\u2011line PD\u2011L1\u2011positive NSCLC, marking the first ADC\u2011plus\u2011immune checkpoint inhibitor regimen to reach a primary endpoint in front\u2011line NSCLC.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48874","og_locale":"en_US","og_type":"article","og_title":"Kelun-Biotech's Sac-TMT Achieves First ADC-IO NSCLC Success","og_description":"Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac-TMT), its proprietary TROP2 ADC, in combination with pembrolizumab (Keytruda), achieved positive results in the Phase\u202f3 OptiTROP\u2011Lung05 study for first\u2011line PD\u2011L1\u2011positive NSCLC, marking the first ADC\u2011plus\u2011immune checkpoint inhibitor regimen to reach a primary endpoint in front\u2011line NSCLC.","og_url":"https:\/\/flcube.com\/?p=48874","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-24T13:40:48+00:00","article_modified_time":"2025-11-24T13:40:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2405.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48874#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48874"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kelun-Biotech&#8217;s Sac-TMT Achieves First ADC-IO NSCLC Success","datePublished":"2025-11-24T13:40:48+00:00","dateModified":"2025-11-24T13:40:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48874"},"wordCount":351,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48874#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2405.webp","keywords":["ADC \/ XDC","Clinical trial results","HKG: 6990","Kelun-Biotech Biopharmaceutical","MSD"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48874#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48874","url":"https:\/\/flcube.com\/?p=48874","name":"Kelun-Biotech's Sac-TMT Achieves First ADC-IO NSCLC Success - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48874#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48874#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2405.webp","datePublished":"2025-11-24T13:40:48+00:00","dateModified":"2025-11-24T13:40:50+00:00","description":"Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac-TMT), its proprietary TROP2 ADC, in combination with pembrolizumab (Keytruda), achieved positive results in the Phase\u202f3 OptiTROP\u2011Lung05 study for first\u2011line PD\u2011L1\u2011positive NSCLC, marking the first ADC\u2011plus\u2011immune checkpoint inhibitor regimen to reach a primary endpoint in front\u2011line NSCLC.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48874#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48874"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48874#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2405.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2405.webp","width":1080,"height":608,"caption":"Kelun-Biotech's Sac-TMT Achieves First ADC-IO NSCLC Success"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48874#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kelun-Biotech&#8217;s Sac-TMT Achieves First ADC-IO NSCLC Success"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2405.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48874"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48874\/revisions"}],"predecessor-version":[{"id":48877,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48874\/revisions\/48877"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48876"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}